Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719757 | 0.94 | BHMT (0.49) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL7721748 | 0.87 | LMNA (0.64) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL756105 | 0.82 | TSHR (0.71) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL31241576 | 0.79 | TSHR (0.68) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL1251621 | 0.79 | LMNA (0.41) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL7721691 | 0.78 | CYP2D6 (0.48) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL6866613 | 0.77 | LMNA (0.78) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL288365 | 0.77 | LMNA (0.53) | TSHRLMNAKMT2ASLC22A6NFKB1 | |
| SCHEMBL7720625 | 0.77 | CYP2D6 (0.46) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL5566705 | 0.77 | TSHR (0.54) | TSHRLMNAKMT2AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | claimed |
| US-6395930-B1 | AMINE SULFIDE PHOSPHATE OR SULFATE REAGENTS | WARNER LAMBERT | 2002-05-28 | — | — | US | claimed |
| US-20230143949-A1 | MICROBEADS AND USES THEREOF | SHANGHAI POLARIS BIOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4154000-A1 | MICROBEADS AND USES THEREOF | Shanghai Polaris Biology Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| CN-115667926-A | Microbeads and use thereof | 上海宸安生物科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021233303-A1 | MICROBEADS AND USES THEREOF | SHANGHAI POLARIS BIOLOGY CO., LTD. (CN) | 2021-11-25 | — | — | WO | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| EP-2341944-A2 | CONJUGATES OF HEXOSE AND METAL COORDINATING COMPOUNDS FOR IMAGING PURPOSES | Mallinckrodt Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-0971747-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | disclosed |
| EP-0946202-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998052609-A1 | SONODYNAMIC THERAPY USING AN ULTRASOUND SENSITIZER COMPOUND | NYCOMED IMAGING AS (NO) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998048838-A1 | COMPOUNDS | NYCOMED IMAGING AS (NO) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998047541-A1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-10-29 | — | — | WO | disclosed |
| US-5817774-A | Unsymmetrical complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | STERLING WINTHROP INCORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998018496-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998018497-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| US-5559214-A | Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods | STERLING WINTHROP INC. (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | TSHR 2360/4885LMNA 4406/4885KMT2A 2498/4885 |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | SLC2A1, SLC2A4, SLC2A3 | TSHR 2360/4885LMNA 4406/4885KMT2A 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.